Risk, Prevalence and Survival Outcomes of Ovarian Cancer in Women With Endometriosis: The Endocancer Systematic Review and Meta-Analysis.

J Minim Invasive GynecolMay 6, 2026 (epub)
Clinical ResearchObstetrics & GynecologyOncology (Medical)

Ilaria Piacenti, Veronica Tius, Benedetta Gomba et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between endometriosis and ovarian cancer risk and survival outcomes in over 500,000 women. The study found that endometriosis increased the risk of ovarian cancer (OR: 1.82) and was associated with improved survival in endometriosis-associated ovarian cancer (HR: 0.48), indicating distinct clinicopathologic features.

Key findings

  • Endometriosis increased ovarian cancer risk with an odds ratio of 1.82.
  • Patients with endometriosis-associated ovarian cancer were more often diagnosed with early-stage tumors (OR: 0.29).
  • Overall survival was significantly better in endometriosis-associated ovarian cancer (HR: 0.48).
  • Clear cell and endometrioid histotypes predominated in endometriosis-associated ovarian cancer.

Why it matters

Understanding the link between endometriosis and ovarian cancer risk is crucial for clinicians in providing personalized counseling and risk stratification for affected patients. Improved survival outcomes in endometriosis-associated ovarian cancer highlight the need for tailored management strategies.

Source

PubMed · PMID 42102910

Published in J Minim Invasive Gynecol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.